Responsive Neurostimulation Reduces Focal Seizures by 82% at Three Years

Expanding the Neuromodulation Toolkit for Refractory Focal Epilepsy

Managing drug-resistant focal epilepsy remains a significant clinical challenge, as approximately one-third of patients continue to experience disabling seizures despite trials of multiple antiseizure medications [1, 2]. When resective surgery is not feasible, clinicians often utilize neuromodulation modalities such as vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation (a closed-loop system that monitors brain activity and delivers targeted electrical pulses to interrupt detected ictal patterns) [3, 4]. While these therapies have established efficacy in randomized controlled trials, the transition to real-world clinical practice often reveals variations in long-term outcomes and safety profiles [5, 6]. Long-term monitoring is particularly critical for assessing the risk of sudden unexplained death in epilepsy (a fatal complication where a patient dies without a clear structural or toxicological cause), which remains a primary concern in this patient population [7]. A new prospective study now offers fresh insights into the longitudinal performance and safety of responsive neurostimulation in a large clinical cohort, providing practicing neurologists with clearer expectations for long-term patient management.

Real-World Performance in a Large Multicenter Cohort

Following the initial approval of the RNS System, the Food and Drug Administration mandated a prospective postapproval study to determine if the safety and effectiveness observed in clinical practice aligned with the results from earlier randomized controlled trials. This open-label study was designed to evaluate the device in a real-world setting, enrolling adult participants who met the specific indication for drug-resistant focal epilepsy (seizures originating in one or two discrete brain areas that do not respond to at least two appropriately chosen antiseizure medications). By moving beyond the highly controlled environment of a randomized trial, the researchers aimed to capture data that more accurately reflects the diverse patient populations and varied programming strategies encountered in daily clinical practice. The study was conducted across 32 US epilepsy centers, providing a broad geographic and institutional sample. A total of 324 patients were implanted with the responsive neurostimulation device, with a mean age of 37.1 years and a demographic composition that was 59.6% female. To ensure the robustness of the longitudinal data, the researchers tracked these individuals over several years, with 271 patients completing the full 3-year follow-up period. The primary effectiveness end point was defined as the median percent change in seizure frequency at 3 years of treatment, comparing the number of seizures experienced during the treatment period to the patient's baseline frequency. This investigation provides Class IV evidence (data derived from observational studies or case series lacking a randomized control group) that direct brain-responsive neurostimulation effectively reduces seizure frequency in adults with refractory focal-onset seizures. Crucially, the study found that these reductions were achieved without serious adverse events throughout the 3-year observation window. By establishing this safety and efficacy profile in a large multicenter cohort, the findings offer clinicians a clearer understanding of what to expect when implementing this technology, particularly regarding the long-term management of patients who have exhausted pharmacological options.

Sustained Seizure Reduction and Clinical Response Rates

The longitudinal data from this postapproval study demonstrate a progressive improvement in seizure control over the three-year observation period. At the 6-month mark, the median percent reduction in seizure frequency was 62%. This clinical response continued to strengthen through the end of the study, reaching a median percent reduction of 82% at 3 years (p < 0.0001; Wilcoxon signed-rank test). These findings suggest that the therapeutic effect of responsive neurostimulation is not only sustained but may actually improve as clinicians refine stimulation parameters based on the electrocorticographic data (the electrical activity of the brain recorded directly from the cortex) provided by the device. Beyond median reductions, the study highlights a substantial cohort of high responders who achieved near-complete seizure control. Specifically, 41% of participants achieved a 90% or greater reduction in seizure frequency at 3 years. For many patients, this reduction translated into extended periods of complete seizure freedom, a critical metric for restoring functional independence and improving quality of life. The researchers found that 42.5% of participants experienced at least one seizure-free period lasting 6 months or more, while 22.0% experienced seizure freedom for 12 months or more. These rates of prolonged seizure freedom are particularly notable in a population with refractory epilepsy that has historically failed to respond to multiple medications. The clinical utility of the system appeared consistent across diverse patient presentations, regardless of the complexity or location of the seizure focus. Effectiveness was similar across patients with 1 or 2 seizure onsets, indicating that the device can successfully manage multifocal disease that might otherwise preclude resective surgery. Furthermore, the effectiveness was similar across onset locations, including the mesial temporal lobe (the deep, internal structures of the temporal lobe often implicated in memory and emotion), the neocortical regions (the outer layer of the cerebral hemispheres), or cases involving both mesial temporal and neocortical regions. This broad efficacy across different anatomical substrates suggests that responsive neurostimulation is a versatile option for various focal epilepsy phenotypes encountered in clinical practice.

Safety Profile and Reduced SUDEP Risk

The safety profile of the responsive neurostimulation system in this real-world setting remained consistent with earlier clinical trials, reinforcing its tolerability for long-term use. Throughout the three-year follow-up period, no serious stimulation-related adverse events were reported among the study participants. Although the primary safety endpoint analysis is scheduled for 5 years of treatment, these interim safety data provide clinicians with evidence of the device's stability in a broad patient population. The absence of serious complications directly attributable to the electrical stimulation suggests that the device can be safely managed in an outpatient setting without introducing significant new procedural or therapy-related risks. A critical component of the safety evaluation involved assessing the risk of sudden unexplained death in epilepsy, a leading cause of mortality in patients with poorly controlled seizures. By combining data from all RNS System trials (n = 645), the researchers determined that the sudden unexplained death in epilepsy rate was 2.3/1,000 patient years. This rate was significantly lower than predefined comparators (p < 0.05; 1-tailed χ2), which are historical benchmarks representing the expected mortality rates in similar populations of patients with drug-resistant epilepsy. These findings indicate that the clinical benefits of responsive neurostimulation extend beyond seizure reduction, potentially offering a protective survival effect for high-risk patients.

Evolution of Programming and Future Directions

The clinical outcomes observed in this prospective study indicate a shift in the therapeutic trajectory of responsive neurostimulation. The researchers found that seizure reductions in this study were greater and achieved faster than those reported in the original randomized controlled trial and subsequent long-term treatment trials. Specifically, the median reduction in seizure frequency reached 62% by only six months, a pace of improvement that exceeded earlier clinical investigations. These results were similar to a more recent retrospective multicenter real-world study, reinforcing the observation that contemporary clinical outcomes are consistently surpassing the benchmarks established during the initial regulatory trials. The authors suggest that these improvements in efficacy may reflect changes in programming practices that have matured since the device was first introduced. As clinicians have become more adept at interpreting the electrocorticography (the continuous brain wave data recorded directly from the cerebral cortex) provided by the system, they have been able to refine the parameters for seizure detection and electrical delivery. Consequently, future research will focus on using brain data obtained by the device to optimize detection and stimulation paradigms for each patient. By leveraging this longitudinal intracranial data, physicians may eventually be able to transition from standardized settings to highly personalized neurostimulation protocols that respond more precisely to an individual patient's unique seizure signatures, ultimately improving long-term disease management.

References

1. Khorkhash KMM, El-Shazly AA, Fayed ZYI, Hefny SM. Responsive Neuro-Stimulation versus Deep Brain Stimulation in Drug Resistant Focal Epilepsy: A Systematic Review. The Quarterly journal of medicine. 2024. doi:10.1093/qjmed/hcae175.564

2. Kwon C, Ripa V, Al-Awar O, Panov F, Ghatan S, Jetté N. Epilepsy and Neuromodulation—Randomized Controlled Trials. Brain Sciences. 2018. doi:10.3390/brainsci8040069

3. Skrehot HC, Englot DJ, Haneef Z. Neuro-stimulation in focal epilepsy: A systematic review and meta-analysis.. Epilepsy & behavior : E&B. 2023. doi:10.1016/j.yebeh.2023.109182

4. Rolston JD, Englot DJ, Wang DD, Shih T, Chang EF. Comparison of seizure control outcomes and the safety of vagus nerve, thalamic deep brain, and responsive neurostimulation: evidence from randomized controlled trials. Neurosurgical FOCUS. 2012. doi:10.3171/2012.1.focus11335

5. Vetkas A, Fomenko A, Germann J, et al. Deep brain stimulation targets in epilepsy: Systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus. Epilepsia. 2022. doi:10.1111/epi.17157

6. Haneef Z, Skrehot HC. Neurostimulation in generalized epilepsy: A systematic review and meta‐analysis. Epilepsia. 2023. doi:10.1111/epi.17524

7. Eliashiv D, Rao VR, Jobst BC, et al. Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy: Three-Year Efficacy and Interim Safety Results.. Neurology. 2026. doi:10.1212/WNL.0000000000214875